Headache
| Migraine
Headache
Migraine

Characteristics of Individuals with Migraine Who Are Eligible for Novel CGRP Monoclonal Antibodies: Results of the OVERCOME Study

book_2 Source: AHSAM 2020 - Oral session Published on July 30, 2020
calendar_today Published on Medfyle: July 2020
import_contacts 6 min
headphones 1 min

In this medfyle

Expert commentary by Carrie Dougherty, MD, FAHS

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Acknowledgements
Read more arrow_downward Hide arrow_upward

This is a highlights summary of an oral session given at the AHSAM 2020 Virtual Annual Scientific Meeting and presented by:

Richard B. Lipton, MD
Professor and Vice Chair of Neurology
Albert Einstein College of Medicine
Bronx, New York

The content is produced by Infomedica, the official reporting partner of ASHAM 2020 Virtual Annual Scientific Meeting. The summary text was drafted by Goldcrest Medical Writing, reviewed by Marco Vercellino, MD, an independent external expert, and approved by Jessica Ailani, MD, FAHS and Mark J. Burish, MD, PhD, the scientific editors of the program.

The presenting authors of the original session had no part in the creation of this conference highlights summary.

In addition, an expert commentary on the topic has been provided by:

Carrie Dougherty, MD, FAHS
Associate Professor of Neurology
Fellowship Program Director, Headache Medicine
Assistant Residency Program Director, Neurology
MedStar Georgetown University Hospital

About the Expert
Read more arrow_downward Hide arrow_upward

Carrie Dougherty, MD, FAHS
Associate Professor of Neurology
Fellowship Program Director, Headache Medicine
Assistant Residency Program Director, Neurology
MedStar Georgetown University Hospital

Carrie Dougherty, MD, is associate professor of neurology and program director of the headache medicine fellowship at MedStar Georgetown University Hospital in Washington, DC. She is a fellow of the American Headache Society and serves as a member of the Guidelines committee and the Scottsdale Headache Symposium Planning committee. She is secretary of the Southern Headache Society and the Alliance for Headache
Disorders Advocacy.

References
Read more arrow_downward Hide arrow_upward

1. American Headache Society. The American Headache Society Position Statement on Integrating New Migraine Treatments Into Clinical Practice. Headache 2019;59:1-18.

2. Silberstein SD, et al. Evidence-based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-1345.

3. Lipton RB, et al. Cutaneous Allodynia in the Migraine Population. Annals of Neurology 2008;63:148-158.

4. Lipton RB, et al. Validity and Reliability of the Migraine-Treatment Optimization Questionnaire. Cephalalgia 2009;29:751-759.

5. Stewart WF, et al. Development and Testing of the Migraine Disability Assessment (MIDAS) Questionnaire to Assess Headache-Related Disability. Neurology 2001;56(6 Supp 1):S20-28.


Feedback